Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients

Laminar Pharmaceuticals, S.A. Spain

References:

Leske, H., Camenisch Gross, U., Hofer, S., Neidert, M. C., Leske, S., Weller, M., ... & Rushing, E. J. (2023). MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value. Acta Neuropathologica Communications, 11(1), 139

Logo - https://mma.prnewswire.com/media/2435866/Laminar_Pharmaceuticals_SA_Logo_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/laminar-pharma-announces-first-open-label-progression-free-survival-data-for-lam561-in-combination-with-standard-of-care-in-first-line-therapy-for-newly-diagnosed-glioblastoma-mgmt-methylated-patients-302393058.html